卡铂新辅助动脉化疗联合瘤内注射力尔凡治疗晚期宫颈癌的临床观察  

Clinical Observation of Neoadjuvant Artery Chemotherapy with Carboplatin and Intratumoral Injection of Lifein for Advanced Cervical Cancer

作　　者：宋建平[1] 

机构地区：[1]广西科技大学第一附属医院妇产科,545002

出　　处：《实用癌症杂志》2014年第5期531-534,共4页The Practical Journal of Cancer

摘　　要：目的：探讨卡铂新辅助动脉化疗联合瘤内注射力尔凡治疗晚期宫颈癌的临床疗效。方法选择168例晚期宫颈癌患者，并随机分为观察组和对照组，各84例。对照组采用卡铂新辅助化疗治疗，观察组在对照组基础上向肿瘤体内注射力尔凡，比较2组临床疗效。结果观察组Ⅱb期～Ⅳa期总有效率为84．5％，对照组为64．3％，2组比较差异具有统计学意义（P＜0．05）。观察组骨髓抑制发生、胃肠反应、脱发、神经毒性发生率小于对照组（P＜0．05），但发热发生率高于对照组（P＜0．05）。观察组、对照组手术切除率分别为97．6％、90．5％，差异有统计学意义（P＜0．05）。观察组、对照组肿瘤转移率分别为1．2％、8．3％，差异有统计学意义（P＜0．05）。观察组Ⅱb期患者5年生存率为87．0％，对照组为75．0％，差异无统计学意义（P＞0．05）；观察组Ⅲ期患者5年生存率为75．8％，对照组为66．7％，差异无统计学意义（P＞0．05）；观察组1例Ⅳa期患者存活5年2个月，对照组Ⅳa期患者存活期均低于4年。结论卡铂新辅助化疗联合瘤内注射力尔凡治疗晚期宫颈癌，可明显提高化疗的有效率，提高手术切除率，同时降低不良反应及肿瘤转移率，提高了患者远期生存率，值得临床推广。Objective To investigate the clinical efficacy of neoadjuvant artery chemotherapy with carboplatin and intra -tumoral injection of Lifein for advanced cervical cancer .Methods 168 cases of advanced cervical cancer patients were selected and randomly divided into the observation group and the control group ,with 84 cases in each group .The control group were treated with neoadjuvant chemotherapy with carboplatin ,the observation group were treated with intratumoral injection of Lifein on the ba-sis of the control group ,the clinical efficacy of the 2 groups were compared .Results The total effective rates of stage ⅡB toⅣa patients of the observation group and the control group were 84.5%and 64.3%,the difference between the 2 groups was statis-tically significant（P〈0.05）.The incidence rates of bone marrow suppression ,gastrointestinal reactions,alopecia and neurotoxici-ty of the observation group were lower than those of the control group ,the incidence rate of fever of the observation group was higher than that of the control group .The operation resection rates of the observation group and the control group were 97.6%and 90.5%,respectively,the difference between the 2 groups was statistically significant （P〈0.05）.The tumour transfer rates of the observation group and the control group was 1.2% and 8.3%, respectively, the difference was statistically significant （ P 〈0.05）.The 5-year survival rates of ⅡB stage patients of the observation group and the control group were 87% and 75%,there had no statistical difference （P〉0.05）;the 5-year survival rates of Ⅲ stage patients of the observation group and the control group were 75.8%and 66.7%,there had no statistical difference （P〉0.05）.1 Ⅳa stage patient in the observation group sur-vived 5.2 years,while no Ⅳa stage patients in the control group survived more than 4 years.Conclusion Neoadjuvant artery chemotherapy with carboplatin and intratumoral injection of Lifein for advanced cervical cancer can significantly improve chemo

关 键 词：新辅助化疗 力尔凡 宫颈癌 

分 类 号：R737.33[医药卫生—肿瘤]